Perioperative arrhythmias: Prevention, detection, evaluation, therapy;Perioperative arrhythmien: Vermeidung, erkennung, bewertung, therapie

Anaesthesist

Volumn 49, Issue 11, 2000, Pages 985-1002

  Vicenzi, M N ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Amiodarone; Anesthesia; Cardiac arrhythmias; Perioperative risk

Indexed keywords

AMIODARONE; DILTIAZEM; VERAPAMIL;

ANESTHESIA; CONTINUING EDUCATION; DEFIBRILLATOR; HEART ARRHYTHMIA; PERIOPERATIVE PERIOD; QT INTERVAL; RECEPTOR BLOCKING; REVIEW; WOLFF PARKINSON WHITE SYNDROME;

ARRHYTHMIA; HUMANS; INTRAOPERATIVE COMPLICATIONS;

EID: 0033660696     PISSN: 00032417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001010070036     Document Type: Review

References (41)

1. CAST and beyond. Implications of the cardiac arrhythmia suppression trial. Task force of the working group on arrhythmias of the European Society of Cardiology
2. Increased risk of death and cardiac arrest from encainide and flecainide in patients after non-Q-wave acute myocardial infarction in the cardiac arrhythmia suppression trial. CAST investigators
3. Sotalol: An important new antiarrhythmic
4. Perioperative cardiac dysrhythmias: Diagnosis and management
5. The rational use of intravenous amiodarone in the perioperative period
6. Nonsustained ventricular tachycardia in the setting of acute myocardial infarction. Tachycardia characteristics and their prognostic implications
7. Ejection fraction, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhythmias, and plasma norepinephrine as determinants of prognosis in heart failure
8. Prophylactic antiarrhythmic therapy for the prevention of sudden death in high-risk patients: Drugs and devices
9. Evidence-based analysis of amiodarone efficacy and safety
10. Meta-analysis of antiarrhythmic drug trials
11. Antiarrhythmic drugs should be used to suppress ventricular ectopy in the perioperative period
12. Suppression of frequent premature ventricular contractions and improvement of left ventricular function in patients with presumed idiopathic dilated cardiomyopathy
13. Arrhythmias in heart failure: Current concepts of mechanisms and therapy
14. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction. The original design concept of the cardiac arrhythmia suppression trial (CAST)
15. Amiodarone and 'primary' prevention of sudden death: Critical review of a decade of clinical trials
16. Multicenter study of general anesthesia. II. Results
17. Impact of left ventricular hypertrophy on ventricular arrhythmias in the absence of coronary artery disease
18. Magnesium and cardiovascular disease
19. The cardiac arrhythmia suppression trial: First cast...then cast-II
20. Randomised trial of effect of amiodarone on mortality in patients with left-venttitular dysfunction after recent myocardial infarction: EMIAT. European myocardial infarct amiodarone trial investigators
21. Antiarrhythmic drug classifications and the clinician: A gambit in the land of chaos
22. Beta-blocker prevention of proarrhythmia and proischemia: Clues from CAST, CAMIAT, and EMIAT
23. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT II
24. The effects of the new antiarrhythmic E 047/1 on postoperative ischemia-induced arrhythmias in dogs
25. Using the right drug: A treatment algorithm for regular supraventricular tachycardias
26. Perioperative ventricular dysrhythmias in patients with structural heart disease undergoing noncardiac surgery
27. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery
28. Profiles of aprindine, cibenzoline, pilsicainide and pirmenol in the framework of the sicilian gambit
29. Amiodarone: What have we learned from clinical trialsa
30. Amiodarone: Clinical trials
31. Mechanism of lethal proarrhythmia observed in the cardiac arrhythmia suppression trial: Role of adrenergic modulation of drug binding
32. Preoperative assessment of cardiac risk in noncardiac major vascular surgery
33. The 'Sicilian Gambit'. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. The task force of the working group on arrhythmias of the European Society of Cardiology
34. What have clinical trials taught us about proarrhythmiaa
35. The cardiac vulnerable period and reentrant arrhythmias: Targets of anti- and proarrhythmic processes
36. Hemodynamics during ventricular tachyarrhythmias
37. A decade of clinical trials: CAST to AVID
38. Evaluation of the acute electrophysiologic effects of intravenous dronedarone, an amiodarone-like agent, with special emphasis on ventricular repolarization and acquired torsade de pointes arrhythmias
39. Severe ventricular dysrhythmias after cardiac surgery treated with the fast acting amiodarone derivative E 047/1
40. Preoperative serum potassium levels and perioperative outcomes in cardiac surgery patients
41. Use of beta-blockade to prevent death after noncardiac surgery